Low-Field Magnetic Stimulation Does Not Boost Oxygen Levels in Healthy Subjects
A miniaturized PEMF device failed to raise SpO2 in healthy rats, suggesting COVID-19 benefits may be disease-specific.
Summary
Researchers built a small, low-field thoracic magnetic stimulation device and tested whether pulsed electromagnetic fields could raise blood oxygen levels in healthy rats. Earlier studies showed this technology increased oxygen saturation in COVID-19 patients, raising hopes it might benefit healthy people too. The device generated magnetic pulses between 10.5 and 13.1 millitesla — the same range used in human COVID-19 trials. Despite careful monitoring, no statistically significant change in peripheral oxygen saturation was detected in the healthy animals. This suggests the oxygen-boosting effect seen in COVID-19 patients is likely tied to the disease itself rather than a universal physiological response to magnetic stimulation. The findings are an important safety and feasibility checkpoint before any expansion of this technology to healthy human populations.
Detailed Summary
Pulsed electromagnetic field therapy has attracted growing interest as a non-invasive intervention for a range of conditions, including respiratory compromise. Earlier clinical observations reported that low-field thoracic magnetic stimulation raised peripheral oxygen saturation in COVID-19 patients, sparking curiosity about whether the same effect might benefit healthy individuals seeking to optimize respiratory function or recovery.
To investigate this question safely, researchers at Benemérita Universidad Autónoma de Puebla developed a miniaturized low-field thoracic magnetic stimulation device — essentially a compact pulsed electromagnetic field system — and tested it in healthy rats before any human trials. The device used two 30-turn coils powered by a 30-volt DC source, capable of generating magnetic flux densities of 10.5, 11.6, and 13.1 millitesla. A microcontroller-based safety circuit kept coil temperatures below 38°C throughout testing, and a pulse oximeter continuously tracked blood oxygen saturation.
The key result was a null finding: none of the three magnetic field intensities produced a statistically significant change in peripheral oxygen saturation compared to pre-stimulation baseline levels. The healthy rats maintained normal SpO2 regardless of the magnetic pulse applied.
This outcome carries meaningful implications. It suggests that the oxygen improvements previously observed in COVID-19 patients are likely driven by disease-specific mechanisms — perhaps by counteracting hypoxia caused by viral-induced lung inflammation — rather than by any direct enhancement of oxygen uptake in already-healthy respiratory systems. In other words, PEMF may act as a corrective tool rather than a performance enhancer.
For clinicians and researchers, this is a critical distinction. It tempers enthusiasm for using low-field magnetic stimulation as a general wellness or performance optimization tool while keeping the door open for therapeutic applications in hypoxic or diseased states. Further research in animal models of respiratory disease and eventually in human clinical trials will be needed to clarify the mechanism and therapeutic window.
Key Findings
- Low-field thoracic magnetic stimulation (10.5–13.1 mT) did not significantly change SpO2 in healthy rats.
- The miniaturized PEMF device successfully replicated magnetic intensities used in prior COVID-19 human studies.
- Oxygen benefits seen in COVID-19 patients appear disease-specific, not a universal physiological effect.
- The device included a safety circuit maintaining coil temperature below 38°C, enabling safe repeated use.
- Results suggest PEMF may act as a corrective rather than performance-enhancing respiratory intervention.
Methodology
Researchers developed a custom miniaturized PEMF device using two 30-turn coils and an ATmega328P microcontroller to deliver controlled magnetic pulses at 10.5, 11.6, and 13.1 mT to healthy rats. Peripheral oxygen saturation was continuously monitored via a NONIN 750 pulse oximeter, with pre- and post-stimulation SpO2 values compared statistically. The study was conducted in healthy animal models as a preclinical step before potential human trials.
Study Limitations
The study is based on the abstract only, limiting access to full statistical details, sample sizes, and experimental protocols. The animal model may not fully translate to human physiology, and healthy subjects by definition have little room for SpO2 improvement, potentially masking subtle effects. Only a single outcome measure (SpO2) was assessed, leaving other potential physiological effects of PEMF unexplored.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.